·Cash position of £2.4 m provides cash runway until at least the end of April 2020. Leeds, 22 January 2020- Tissue Regenix Group the regenerative medical devices company, provides an unaudited trading update for the year ended 31 December 2019.. Revenue is anticipated to be £13 m, representing an annual increase of 12%.
RNS Number: 7961 Z Tissue Regenix Group PLC 14 January 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7948 Z Tissue Regenix Group PLC 14 January 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2771 U Tissue Regenix Group PLC 21 November 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7943 T Tissue Regenix Group PLC 18 November 2019 Tissue Regenix Group plc. Leeds, 18 November 2019- Tissue Regenix Group the regenerative medical devices company today announces that Chief Financial Officer, Mike Barker, has resigned from his position for personal reasons and will leave the Company at the end of November. Tissue Regenix was formed in...
RNS Number: 4787 T Tissue Regenix Group PLC 14 November 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Leeds, 14 November 2019- Tissue Regenix Group the regenerative medical devices company, announces the terms of a revised agreement that it has entered into with MidCap Financial Trust with regard to the term loan credit facility and revolving credit facility. Following engagement with MidCap the Company has successfully renegotiated the Term Loan,...
RNS Number: 3235 T Tissue Regenix Group PLC 13 November 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3217 T Tissue Regenix Group PLC 13 November 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0096 T Tissue Regenix Group PLC 11 November 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0084 T Tissue Regenix Group PLC 11 November 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Leeds, 11 November 2019- Tissue Regenix Group, the regenerative medical devices company, announces an update in respect of the loan facilities provided by MidCap Financial Trust, further details of which are contained in the Company's announcement on 4 June 2019.. As at 8 November, being the last practicable date ahead of the announcement, the Company had drawn...
RNS Number: 2920 Q Tissue Regenix Group PLC 17 October 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Universal City grant award triggers commencement of facility expansion. Tissue Regenix has received confirmation of a $0.3 m grant from Universal City to support the commencement of the initial phase of the build out programme on the Company's newly leased 21,000 sq.ft. facility in San Antonio, further details of which were announced on 15 August 2019.
RNS Number: 9741 P Tissue Regenix Group PLC 15 October 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5699 O Tissue Regenix Group PLC 03 October 2019 Tissue Regenix Group plc. Leeds, 3 October 2019- Tissue Regenix Group, the regenerative medical devices company, announces the launch of a product line extension,' DermaPure Non- Oriented', specifically tailored for the surgical and trauma markets, which further expands the reach of its flagship dCELL ®...
·Group sales increased to £6.1 m. -DermaPure increased sales by 33% to £2.0 m. ·Cash balance of £10.1 m, post- $7.5 m drawdown under a c redit facility secured for up to $20 m to invest in meeting growing demand for products.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    1.17B

Company Profile

Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products

Classification

Market Indices-

Locations

HQ
Astley Lane Industrial Estate
Astley Way
Unit 1&2, Swillington
Leeds
LS26 8XT
Watchlist